Rho GTPase activating protein: Difference between revisions

Michal Harel (talk | contribs)
No edit summary
Michal Harel (talk | contribs)
No edit summary
 
(11 intermediate revisions by the same user not shown)
Line 2: Line 2:
__TOC__
__TOC__
== Function ==
== Function ==
'''Rho GTPase activating protein''' (RhoGAP) are one of the main classes of Rho GTPase regulators that are crucial in cell cytoskeletal organization, growth, differentiation, neuronal development and synaptic functions<ref>PMID:12480336</ref>.  RhoGAPs contain a RhoGAP domain.
'''Rho GTPase activating protein''' (RhoGAP) are one of the main classes of Rho GTPase regulators that are crucial in cell cytoskeletal organization, growth, differentiation, neuronal development and synaptic functions<ref>PMID:12480336</ref>,<ref>PMID:17222083</ref>.  RhoGAPs contain a RhoGAP domain.
*'''RhoGAP7''' activates the small GTPases RHOA, RHOB, RHOC and CDC42.
*'''RhoGAP9''' regulates adhesion of hematopoietic cells to the extracellular matrix.
*'''RhoGAP11''' causes cell-cycle arrest and apoptosis in response to DNA damage.
*'''RhoGAP12''' may be involved in suppressing tumor formation.
*'''RhoGAP21''' involved in cell adhesion, migration, Golgi regulation, cell trafficking and insulin secretion<ref>PMID:29856495</ref>.
*'''RhoGAP21''' involved in cell adhesion, migration, Golgi regulation, cell trafficking and insulin secretion<ref>PMID:29856495</ref>.
*'''RhoGAP35''' involved in cell adhesion, migration and invasion<ref>PMID:35758029</ref>.


== Relevance ==
== Relevance ==
RhoGAPs are present in altered abundance in a variety of human cancers and may serve as targets for cancer therapy<ref>PMID:16918449</ref>.
RhoGAPs are present in altered abundance in a variety of human cancers and may serve as targets for cancer therapy<ref>PMID:16918449</ref>,<ref>PMID:34365932</ref>.  RhoGAP10 variants may be associated with schizophrenia<ref>PMID:32699248</ref>.


== Structural highlights ==
== Structural highlights ==
Line 14: Line 21:


</StructureSection>
</StructureSection>
==3D structures of Rho GTPase activating protein==
Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}}
{{#tree:id=OrganizedByTopic|openlevels=0|
*RhoGAP 1
**[[1ow3]], [[5m6x]], [[5m70]] - hRhoGAP 1 residues 198-439 + RhoA + GDP - human<br />
**[[6r3v]] - hRhoGAP 1 GTPase-activating domain residues 1-439 + RhoA + GDP + Pi<br />
**[[4wpc]] - yRhoGAP 1 F-BARR domain + inositol phosphate<br />
**[[5my3]] - yRhoGAP 1 RhoGAP domain - yeast<br />
*RhoGAP 2
**[[4rtt]], [[4rug]], [[2gnc]] - hRhoGAP 2 SLIT-ROBO SH3 domain <br />
**[[2dl8]] - hRhoGAP 2 SLIT-ROBO SH3 domain - NMR<br />
*RhoGAP 4
**[[2epd]] - hRhoGAP 4 SH3 domain - NMR<br />
*RhoGAP 5
**[[2ee4]] , [[2ee5]] - hRhoGAP 5 (mutant) RhoGAP domain - NMR<br />
**[[5u4v]] - hRhoGAP 5 pseudoGTPase domain<br />
*RhoGAP 7
**[[3kuq]] - hRhoGAP 7 RhoGAP domain<br />
**[[2kap]], [[2dky]] - hRhoGAP 7 SAM domain - NMR<br />
*RhoGAP 9
**[[2p0d]], [[2p0f]], [[2p0h]] - hRhoGAP 9 pleckstrin homology domain + phosphoinositide<br />
*RhoGAP 10
**[[2mio]] - hRhoGAP 10 SH3 domain - NMR<br />
**[[2j59]] - hRhoGAP 10 ARF-binding domain + ADP-ribosylation factor<br />
* RhoGAP 11
**[[3eap]] - hRhoGAP 11A RhoGAP domain<br />
* RhoGAP 12
**[[6gvc]] - hRhoGAP 12 residues 683-837 + actin + ATP<br />
*RhoGAP 15
**[[3byi]] - RhoGAP 15 residues 262-473<br />
*RhoGAP 20
**[[3msx]] - hRhoGAP 20 RhoGAP domain + RhoA<br />
*RhoGAP 21
**[[2yuy]] - hRhoGAP 21 PDZ domain - NMR<br />
**[[2dhj]] - hRhoGAP 21 pleckstrin homology domain - NMR<br />
*RhoGAP 27
**[[3pp2]] - hRhoGAP 27 pleckstrin homology domain<br />
*RhoGAP 34 or slit-robo RhoGAP 2
**[[5i6j]], [[5i7d]] - hRhoGAP 34<br />
**[[5i6r]] - hRhoGAP 34 (mutant)<br />
*RhoGAP 35
**[[5irc]] - RhoGAP 35 + RhoA - rat<br />
**[[6d4g]] - rRhoGAP 35 + GTP<br />
*RhoGAP


**[[1grn]] - hRhoGAP C-terminal + GTP-binding protein<br />
}}
== References ==
== References ==
<references/>
<references/>
[[Category:Topic Page]]
[[Category:Topic Page]]

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Joel L. Sussman, Alexander Berchansky